Benzinga's Top Pre-Market Gainers
Exelixis (NASDAQ: EXEL) added 10.63% to $7.08 in the pre-market session. Exelixis reported that the US Food and Drug Administration (FDA) has granted priority review for cabozantinib in medullary thyroid cancer.
Jacobs Engineering Group (NYSE: JEC) soared 6.19% to $41.89 in the pre-market trading. Jacobs Engineering is expected to report its third-quarter earnings after the closing bell.
Sprint Nextel (NYSE: S) surged 4.64% to $4.51 in the pre-market session. Sprint Nextel's trailing-twelve-month revenue is $34.63 billion.
Fluor (NYSE: FLR) moved up 4.43% to $52.82 in the pre-market session. Fluor's PEG ratio is 1.23.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.